Trial Profile
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Sugemalimab (Primary) ; Cisplatin; Fluorouracil
- Indications Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms GEMSTONE-101
- Sponsors CStone Pharmaceuticals
- 01 Aug 2022 Results published in the Cancer Immunology Immunotherapy
- 16 Feb 2022 Planned End Date changed from 1 Aug 2022 to 31 Mar 2022.
- 31 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Aug 2022.